Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
At minimum, the marketing claims significantly overstate the likely benefits
DOI: 10.2147/JIR.S391859 [Google Scholar] Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al
2 In the SURMOUNT-1 trial, 25.9% of tirzepatide participants experienced nausea, and 4.37.1% discontinued due to adverse events (depending on dose)
Haines noted that it is still unclear which patients are most likely to lose muscle and how this muscle loss might impact blood sugar control
US$ 22.72
US$ 25.28
US$ 29.66
US$ 20.84
US$ 26.56
US$ 24.48
